ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Rochester, MN, USA:

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Magrolimab

Phase 2

Gilead Sciences
Gilead Sciences

Rochester, Minnesota, United States and 44 other locations

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).The Following drugs will be ...

Active, not recruiting
Inflammatory Breast Cancer (IBC)
Drug: Paclitaxel
Drug: Cyclophosphamide

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Rochester, Minnesota, United States and 3 other locations

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...

Enrolling
Stage IIIA Breast Cancer
Recurrent Breast Carcinoma
Biological: Utomilumab
Biological: Anti-OX40 Antibody PF-04518600

Phase 2

Hope Rugo, MD

Rochester, Minnesota, United States and 11 other locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Rochester, Minnesota, United States and 505 other locations

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

(pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative ...

Enrolling
Hormone Receptor Positive (HR+), HER2-negative Breast Cancer
Triple Negative Breast Cancer
Drug: Paclitaxel
Drug: Carboplatin

Phase 2

Laura M. Spring, MD

Rochester, Minnesota, United States and 9 other locations

A Study to Investigate LYL797 in Adults with Solid Tumors

CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small...

Enrolling
Relapsed Cancer
TNBC - Triple-Negative Breast Cancer
Biological: LYL797

Phase 1

Lyell Immunopharma

Rochester, Minnesota, United States and 17 other locations

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)

with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who car...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: nab-paclitaxel
Drug: placebo

Phase 3

Novartis
Novartis

Rochester, Minnesota, United States and 76 other locations

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in co...

Active, not recruiting
Breast Cancer
Small Cell Lung Cancer
Drug: CYT-0851 in combination with gemcitabine
Drug: CYT-0851 in combination with capecitabine

Phase 1, Phase 2

Cyteir Therapeutics

Rochester, Minnesota, United States and 15 other locations

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

is to evaluate the safety of acasunlimab (also known as GEN1046) as monotherapy and in combination therapies in patients with malignant solid tumors...

Active, not recruiting
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Biological: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Biological: Acasunlimab in combination with docetaxel (in a single expansion cohort)

Phase 1, Phase 2

Genmab
Genmab

Rochester, Minnesota, United States and 56 other locations

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), end...

Active, not recruiting
Castration-resistant Prostate Cancer
Lower Esophageal Cancer
Drug: cabozantinib
Drug: atezolizumab

Phase 1, Phase 2

Exelixis
Exelixis

Rochester, Minnesota, United States and 123 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems